Horn v. Medical Marijuana, Inc.

District Court, W.D. New York·Decided November 22, 2019·No. 1:15-cv-00701·Unknown

Opinion

UNITED STATES DISTRICT COURT WESTERN DISTRICT OF NEW YORK

DOUGLAS J. HORN, et al.,

Plaintiffs, Case # 15-CV-701-FPG v. DECISION AND ORDER

MEDICAL MARIJUANA, INC., et al.,

Defendants.

INTRODUCTION Presently before the Court are the parties’ cross-motions for reconsideration of the Court’s April 17, 2019 Decision and Order, which resolved the parties’ motions for summary judgment.1 For the reasons that follow, Defendants’ motions for reconsideration (ECF Nos. 97, 106) are GRANTED IN PART and DENIED IN PART, and Plaintiffs’ cross-motion for reconsideration (ECF No. 112) is DENIED. LEGAL STANDARD Both sides cite Federal Rule of Civil Procedure 54(b) as the basis for their motions. Rule 54(b) provides: [A]ny order or other decision, however designated, that adjudicates fewer than all the claims or the rights and liabilities of fewer than all the parties does not end the action as to any of the claims or parties and may be revised at any time before the entry of a judgment adjudicating all the claims and all the parties’ rights and liabilities.

1 Plaintiffs initially filed a notice of appeal after the Court issued its Decision and Order. See ECF No. 92. That appeal has since been dismissed, and the Second Circuit issued its mandate on November 12, 2019. See Horn v. Medical Marijuana, Inc., No. 19-1437, ECF No. 45 (dated Nov. 12, 2019); see also Bedasie v. Mr. Z Towing, Inc., No. 13-CV-5453, 2017 WL 6816331, at *3 (E.D.N.Y. Dec. 21, 2017) (stating that jurisdiction returns to the district court after appeal once a mandate is issued). “A district court has the inherent power to reconsider and modify its interlocutory orders prior to the entry of judgment . . . .” United States v. LoRusso, 695 F.2d 45, 53 (2d Cir. 1982). A litigant seeking reconsideration must set forth “controlling decisions or data that the court overlooked—matters, in other words, that might reasonably be expected to alter the

conclusion reached by the court.” Richard v. Dignean, 126 F. Supp. 3d 334, 337 (W.D.N.Y. 2015); see also Micolo v. Fuller, No. 6:15-CV-06374, 2017 WL 2297026, at *2 (W.D.N.Y. May 25, 2017) (“To merit reconsideration under Rule 54(b), a party must show ‘an intervening change of controlling law, the availability of new evidence, or the need to correct a clear error or prevent a manifest injustice.’”). BACKGROUND In their motions, both sides take issue with the Court’s ruling on whether “Dixie X Dew Drops”—the product at issue—constituted a controlled substance under the federal Controlled Substances Act (“CSA”). See ECF No. 97-3 at 4; ECF No. 112-3 at 3. Some background may be helpful.

Dixie X is a CBD oil. “CBD is short for ‘cannabidiol,’ and it is one of the ‘unique molecules’ found in the Cannabis sativa plant.” Horn v. Med. Marijuana, Inc., 383 F. Supp. 3d 114, 119 (W.D.N.Y. 2019) (internal citation omitted). The Cannabis sativa plant is the plant from which marijuana and hemp are derived. Id. The difference between the two is that “drug-use cannabis is produced from the flowers and leaves of certain strains of the plant, while industrial- use [hemp] is typically produced from the stalks and seeds of other strains of the plant.” Id. This leads to differences in the concentration of tetrahydrocannabinol (“THC”) in each variety. THC is “the substance that gives marijuana its psychoactive properties.” Id. In 2012, the time of the relevant events, the general rule was that all parts and derivatives of the Cannabis sativa plant were defined as “marijuana” and prohibited under the CSA.2 See id. at 123 (citing 21 U.S.C. §§ 802(16), 841(a)(1)). Despite its low THC content and lack of psychoactive effect, the industrial hemp plant and any derivatives fell within this definition

because hemp “is a variety of the Cannabis sativa plant.” Id.; United States v. White Plume, 447 F.3d 1067, 1073 (8th Cir. 2006) (noting that “the CSA does not distinguish between marijuana and hemp”). But the CSA carved out several exceptions to this general rule. Specifically, “[e]xcluded from the definition of marijuana were certain parts of the plant that are incapable of germination: (1) the mature stalks of the Cannabis sativa plant, (2) fiber produced from the stalks of the Cannabis sativa plant, (3) oil or cake made from the seeds of the Cannabis sativa plant, (4) any compound, manufacture, salt, derivative, mixture, or preparation of the mature stalks, fiber, oil, or cake[], and (5) the sterilized seed of the Cannabis sativa plant.” Horn, 383 F. Supp. 3d at 123. Importantly, however, “resin extracted from mature hemp stalks was not excepted from the

definition of marijuana.” Id.; see also 21 U.S.C. § 802(16) (2012). As a result, hemp-based products could only be lawfully manufactured and sold in the United States to the extent they were derived from excepted parts of the Cannabis sativa plant (and thus were not considered marijuana under the CSA). But there was another wrinkle: the CSA also separately prohibited THC, see 21 U.S.C. § 812(c)(17), and many hemp-based products contain “trace amounts of THC.” Hemp Indus. Ass’n v. Drug Enforcement Admin., 333 F.3d 1082, 1085 (9th Cir. 2003) [hereinafter “Hemp I”]. This

2 The CSA has since been amended to legalize industrial hemp production. See Horn, 383 F. Supp. 3d at 124 (discussing legislative history). raised a question: were products made from excepted parts of the Cannabis sativa plant nonetheless unlawful because they contained miniscule, non-psychoactive amounts of THC? In a pair of cases from the early 2000s, the Ninth Circuit answered that question in the negative. See Hemp I, 333 F.3d at 1089-90; Hemp Indus. Ass’n v. Drug Enforcement Admin., 357

F.3d 1012 (9th Cir. 2004) [hereinafter “Hemp II”]. First, it held that the prohibition against THC referred to synthetic, not naturally occurring, THC. See Hemp I, 333 F.3d at 1089-90; Hemp II, 357 F.3d at 1017. Second, it held that products made from excepted parts of the Cannabis sativa plant “were not included in the definition of marijuana—and therefore were not unlawful under the CSA—even if they contained trace amounts of [naturally occurring] THC.” Horn, 383 F. Supp. 3d at 123. The Ninth Circuit reviewed the legislative history and concluded that “Congress ‘knew what it was doing’ when it chose to exempt certain derivatives from the definition of marijuana notwithstanding the presence of trace amounts of THC.” Id. at 124. Based on these conclusions, the Ninth Circuit invalidated new DEA regulations to the extent they purported to ban hemp-based products that contained trace amounts of naturally

occurring THC. See Hemp II, 357 F.3d at 1018-19. But products containing synthetic THC or marijuana were still prohibited under the CSA. See Horn, 383 F. Supp. 3d at 124. This Court relied on the above authority to conclude that, in 2012, Dixie X was a controlled substance. See Horn, 383 F. Supp. 3d at 124. Given the apparent absence of dispute, the Court proceeded on the assumption that Dixie X’s CBD byproduct constituted a resin extracted from the mature stalk. See id. at 124.

Free access — add to your briefcase to read the full text and ask questions with AI

Horn v. Medical Marijuana, Inc., (W.D.N.Y. 2019).

Horn v. Medical Marijuana, Inc. (Horn v. Medical Marijuana, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Anza v. Ideal Steel Supply Corp.
547 U.S. 451 (Supreme Court, 2006)
United States v. Vito Lorusso and Joseph Errante
695 F.2d 45 (Second Circuit, 1982)
Cofacredit, S.A. v. Windsor Plumbing Supply Co. Inc.
187 F.3d 229 (Second Circuit, 1999)
Ferri v. Berkowitz
678 F. Supp. 2d 66 (E.D. New York, 2009)
United States v. White Plume
447 F.3d 1067 (Eighth Circuit, 2006)
Camarda v. Selover
673 F. App'x 26 (Second Circuit, 2016)
Reich v. Betancourt Lopez
858 F.3d 55 (Second Circuit, 2017)
Howard v. America Online Inc.
208 F.3d 741 (Ninth Circuit, 2000)
Noone v. Town of Palmer
2 F. Supp. 3d 1 (D. Massachusetts, 2014)
Richard v. Dignean
126 F. Supp. 3d 334 (W.D. New York, 2015)
Flexborrow LLC v. TD Auto Finance LLC
255 F. Supp. 3d 406 (E.D. New York, 2017)
SLSJ, LLC v. Kleban
277 F. Supp. 3d 258 (D. Connecticut, 2017)
Horn v. Med. Marijuana, Inc.
383 F. Supp. 3d 114 (W.D. New York, 2019)